Unveiling signaling pathways inducing MHC class II expression in neutrophils.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 05 06 2024
accepted: 10 09 2024
medline: 15 10 2024
pubmed: 15 10 2024
entrez: 15 10 2024
Statut: epublish

Résumé

Gram-negative bacillary bacteremia poses a significant threat, ranking among the most severe infectious diseases capable of triggering life-threatening sepsis. Despite the unambiguous involvement of neutrophils in this potentially fatal disease, there are limited data about the molecular signaling mechanisms, phenotype, and function of human neutrophils during the early phase of gram-negative bacillary bacteremia. By using an unbiased proteomics and flow cytometry approach, we identified an antigen-presenting cell (APC)-like phenotype in human peripheral blood neutrophils (PMN) with MHC class II molecule expression in the early phase of bacteremia. Using an in-vitro model of GM-CSF-mediated induction of APC-like phenotype in PMN, we investigated downstream signaling pathways leading to MHC class II expression. GM-CSF stimulation of neutrophils leads to the activation of three major signaling pathways, the JAK-STAT, the mitogen-activated protein kinase (MAPK), and the phosphoinositide 3-kinase (PI3K)-Akt-mTOR pathways, while MHC class II induction is mediated by a MAPK-p38-MSK1-CREB1 signaling cascade and the MHC class II transactivator CIITA in a strictly JAK1/2 kinase-dependent manner. This study provides new insights into the signaling pathways that induce MHC class II expression in neutrophils, highlighting the potential for therapeutic targeting of JAK1/2 signaling in the treatment of gram-negative bacteremia and sepsis. Understanding these mechanisms may open up novel approaches for managing inflammatory responses during sepsis.

Identifiants

pubmed: 39403371
doi: 10.3389/fimmu.2024.1444558
pmc: PMC11472776
doi:

Substances chimiques

Histocompatibility Antigens Class II 0
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1
MHC class II transactivator protein 0
Trans-Activators 0
Nuclear Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1444558

Informations de copyright

Copyright © 2024 Forrer, Palianina, Stühler, Kreuzaler, Roux, Li, Schmutz, Burckhardt, Franzeck, Finke, Schmidt, Bumann and Khanna.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Pascal Forrer (P)

Department of Biomedicine, University and University Hospital of Basel, Basel, Switzerland.

Darya Palianina (D)

Department of Biomedicine, University and University Hospital of Basel, Basel, Switzerland.

Claudia Stühler (C)

Department of Biomedicine, University and University Hospital of Basel, Basel, Switzerland.

Matthias Kreuzaler (M)

Department of Biomedicine, University and University Hospital of Basel, Basel, Switzerland.

Julien Roux (J)

Bioinformatics Core Facility, Department Biomedicine, University and University Hospital of Basel, Basel, Switzerland.
Swiss Institute of Bioinformatics, Department Biomedicine, Basel, Switzerland.

Jiagui Li (J)

Focal Area Infection Biology, Biozentrum, University of Basel, Basel, Switzerland.

Christoph Schmutz (C)

Biozentrum, University of Basel, Basel, Switzerland.

David Burckhardt (D)

Department of Biomedicine, University and University Hospital of Basel, Basel, Switzerland.

Fabian Franzeck (F)

Department of Biomedicine, University and University Hospital of Basel, Basel, Switzerland.

Daniela Finke (D)

Department of Biomedicine, University and University Children's Hospital of Basel, Basel, Switzerland.

Alexander Schmidt (A)

Proteomics Core Facility, Biozentrum, University of Basel, Basel, Switzerland.

Dirk Bumann (D)

Focal Area Infection Biology, Biozentrum, University of Basel, Basel, Switzerland.

Nina Khanna (N)

Department of Biomedicine, University and University Hospital of Basel, Basel, Switzerland.
Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH